

Samia Mora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/614047/publications.pdf>

Version: 2024-02-01

211
papers

28,149
citations

14614

66
h-index

5663

162
g-index

216
all docs

216
docs citations

216
times ranked

31762
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia—a randomized controlled feeding trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 154-162.	2.2	55
2	Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 525-537.	1.8	4
3	Mediterranean Diet Social Network Impact along 11 Years in the Major US Media Outlets: Thematic and Quantitative Analysis Using Twitter. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 784.	1.2	7
4	Association of Modifiable Lifestyle Factors with Plasma Branched-Chain Amino Acid Metabolites in Women. <i>Journal of Nutrition</i> , 2022, 152, 1515-1524.	1.3	6
5	Managing Atherosclerotic Cardiovascular Risk in Young Adults. <i>Journal of the American College of Cardiology</i> , 2022, 79, 819-836.	1.2	72
6	Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1501-1510.	2.2	17
7	Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1490-1500.	2.2	71
8	Red blood cell fatty acid patterns from 7 countries: Focus on the Omega-3 index. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2022, 179, 102418.	1.0	21
9	Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization. <i>JACC: Heart Failure</i> , 2022, 10, 227-234.	1.9	8
10	Whom to Treat for Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>JAMA Internal Medicine</i> , 2022, 182, 587.	2.6	4
11	The Curious Case of Synergy between Lipoprotein (a), Coronary Calcification, and Cardiovascular Disease Risk. <i>Clinical Chemistry</i> , 2022, 68, 1235-1237.	1.5	1
12	Fasting status and metabolic health in relation to plasma branched chain amino acid concentrations in women. <i>Metabolism: Clinical and Experimental</i> , 2021, 117, 154391.	1.5	8
13	Nonfasting Lipids for All Patients?. <i>Clinical Chemistry</i> , 2021, 67, 41-45.	1.5	7
14	Association of obesity indices with in-hospital and 1-year mortality following acute coronary syndrome. <i>International Journal of Obesity</i> , 2021, 45, 358-368.	1.6	8
15	Effects of Vitamin D3 Supplementation on Body Composition in the VITamin D and Omega-3 Trial (VITAL). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1377-1388.	1.8	18
16	Marine Omega-3 Fatty Acids and Cardiovascular Disease Prevention: Seeking Clearer Water. <i>Mayo Clinic Proceedings</i> , 2021, 96, 277-279.	1.4	7
17	Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1061.	3.8	73
18	SARS2 simplified scores to estimate risk of hospitalization and death among patients with COVID-19. <i>Scientific Reports</i> , 2021, 11, 4945.	1.6	19

#	ARTICLE	IF	CITATIONS
19	Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. <i>JAMA Cardiology</i> , 2021, 6, 437.	3.0	82
20	Abstract 019: Modifiable Lifestyle Factors And Plasma Branched Chain Amino Acids: An Analysis Of N=19,472 US Women. <i>Circulation</i> , 2021, 143, .	1.6	1
21	Misperceptions and management of risk: Ongoing challenges in women's cardiovascular health. <i>Atherosclerosis</i> , 2021, 324, 109-111.	0.4	4
22	Branched-Chain Amino Acids and Risk of Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab059.	1.4	12
23	Risk Factors for Premature Myocardial Infarction: A Systematic Review and Meta-analysis of 77 Studies. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 783-794.	1.2	18
24	Sugar-Sweetened Beverage Consumption May Modify Associations Between Genetic Variants in the CHREBP (Carbohydrate Responsive Element Binding Protein) Locus and HDL-C (High-Density Lipoprotein) Tj ETQq0,0,0 rgBT /Overlock 1 e003288.	1.6	8
25	Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003330.	1.6	19
26	Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study. <i>Thyroid</i> , 2021, 31, 1305-1315.	2.4	13
27	A Still-Ignored Cardiovascular Risk Factorâ€”A History of Preeclampsiaâ€”Reply. <i>JAMA Cardiology</i> , 2021, 6, 1098.	3.0	0
28	Lifelong low Lp(a) levels: genetics give a green light?. <i>European Heart Journal</i> , 2021, 42, 1157-1159.	1.0	7
29	Assessing the dyslipidemias: to fast or not to fast?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 97-103.	1.2	1
30	Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions. <i>Neurology</i> , 2021, 97, e2223-e2235.	1.5	7
31	1102â€¦Fish oil supplementation and pro-inflammatory and pro-resolving lipid mediators in patients with and without systemic lupus erythematosus. , 2021, , .		1
32	Exercise-Induced Ventricular Ectopy andÂ Cardiovascular Mortality in Asymptomatic Individuals. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2267-2277.	1.2	20
33	Glycosylation and Cardiovascular Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1325, 307-319.	0.8	9
34	Abstract 11848: Biomarkers of Glucose-Insulin Homeostasis, Randomized Treatment With Omega-3 and Vitamin D Supplementation, and Incident Type 2 Diabetes: Prospective Analysis From the Vitamin D and Omega-3 Trial (VITAL). <i>Circulation</i> , 2021, 144, .	1.6	0
35	The association of cardiovascular mortality with a first-degree family member history of different cardiovascular diseases. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 816-824.	0.2	1
36	Abstract 12860: Effects of Marine Omega-3 and Vitamin D Supplementation on Circulating Biomarkers of Glucose-Insulin Homeostasis and Incident Cardiovascular Disease in the Vitamin D and Omega-3 Trial (VITAL). <i>Circulation</i> , 2021, 144, .	1.6	0

#	ARTICLE	IF	CITATIONS
37	Premature Myocardial Infarction in the Middle East and North Africa: Rationale for the Gulf PREVENT Study. <i>Angiology</i> , 2020, 71, 17-26.	0.8	14
38	Supplementation With Vitamin D and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization. <i>Circulation</i> , 2020, 141, 784-786.	1.6	41
39	Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and Omega-3 Trial (VITAL). <i>Journal of Bone and Mineral Research</i> , 2020, 35, 883-893.	3.1	69
40	Lp(a)'s Odyssey. <i>Journal of the American College of Cardiology</i> , 2020, 75, 145-147.	1.2	3
41	Hypothyroidism and Kidney Function: A Mendelian Randomization Study. <i>Thyroid</i> , 2020, 30, 365-379.	2.4	27
42	Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence. <i>Circulation Research</i> , 2020, 126, 112-128.	2.0	45
43	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 496-517.	1.4	119
44	Circulating branched-chain amino acids and long-term risk of obesity-related cancers in women. <i>Scientific Reports</i> , 2020, 10, 16534.	1.6	22
45	Probabilistic identification of saccharide moieties in biomolecules and their protein complexes. <i>Scientific Data</i> , 2020, 7, 210.	2.4	4
46	One-Year Effects of Omega-3 Treatment on Fatty Acids, Oxylipins, and Related Bioactive Lipids and Their Associations with Clinical Lipid and Inflammatory Biomarkers: Findings from a Substudy of the Vitamin D and Omega-3 Trial (VITAL). <i>Metabolites</i> , 2020, 10, 431.	1.3	13
47	Anti-inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016507.	1.6	21
48	Concordance of Cardiovascular Risk Factors and Behaviors in a Multiethnic US Nationwide Cohort of Married Couples and Domestic Partners. <i>JAMA Network Open</i> , 2020, 3, e2022119.	2.8	26
49	Effects of a Low-Carbohydrate Diet on Cardiometabolic Risk Factors During Weight-Loss Maintenance: A Randomized Controlled Feeding Trial. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa049_018.	0.1	1
50	Habitual Fish Consumption, n-3 Fatty Acids, and Nuclear Magnetic Resonance Lipoprotein Subfractions in Women. <i>Journal of the American Heart Association</i> , 2020, 9, e014963.	1.6	14
51	Quantum approximate Bayesian computation for NMR model inference. <i>Nature Machine Intelligence</i> , 2020, 2, 396-402.	8.3	12
52	Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and Omega-3 Trial. <i>Journal of Clinical Lipidology</i> , 2020, 14, 241-251.	0.6	17
53	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. <i>Atherosclerosis</i> , 2020, 294, 46-61.	0.4	137
54	Association of the Mediterranean Diet With Onset of Diabetes in the Women's Health Study. <i>JAMA Network Open</i> , 2020, 3, e2025466.	2.8	28

#	ARTICLE	IF	CITATIONS
55	Abstract 13479: Association of Plasma Branched Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. <i>Circulation</i> , 2020, 142, .	1.6	1
56	Abstract 16278: Discordant Lipid Phenotype and Other Determinants of Statin Response in the Pravastatin Inflammation/crp Evaluation (PRINCE) Trial. <i>Circulation</i> , 2020, 142, .	1.6	0
57	Cholesterol Insights and Controversies From the UK Biobank Study. <i>Circulation</i> , 2019, 140, 553-555.	1.6	8
58	Statistical Workflow for Feature Selection in Human Metabolomics Data. <i>Metabolites</i> , 2019, 9, 143.	1.3	55
59	A little more time around the track may go a long way: Implications of increasing moderate to vigorous physical activity in pre-adolescents. <i>Atherosclerosis</i> , 2019, 288, 160-162.	0.4	0
60	Perspectives on the Changing Landscape of Measuring Cardiovascular Risk Related to LDL. <i>Clinical Chemistry</i> , 2019, 65, 1487-1492.	1.5	3
61	Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. <i>Clinical Chemistry</i> , 2019, 65, 1508-1521.	1.5	23
62	Serum 25-hydroxyvitamin D in the VITamin D and Omega-3 Trial (VITAL): Clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment. <i>Contemporary Clinical Trials</i> , 2019, 87, 105854.	0.8	24
63	Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 144.	3.0	64
64	The novel inflammatory marker GlycA and the prevalence and progression of valvular and thoracic aortic calcification: The Multi-Ethnic Study of Atherosclerosis. <i>Atherosclerosis</i> , 2019, 282, 91-99.	0.4	23
65	Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trialâ€“Lipid Lowering Arm. <i>JAMA Internal Medicine</i> , 2019, 179, 898.	2.6	46
66	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. <i>Current Vascular Pharmacology</i> , 2019, 17, 538-540.	0.8	23
67	Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment. <i>Thyroid</i> , 2019, 29, 760-777.	2.4	61
68	Thyroid and Cardiovascular Disease. <i>Circulation</i> , 2019, 139, 2892-2909.	1.6	51
69	Group IIA Secretory Phospholipase A ₂ , Vascular Inflammation, and Incident Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1182-1190.	1.1	25
70	GlycA, a Novel Inflammatory Marker and Its Association With Peripheral Arterial Disease and Carotid Plaque: The Multi-Ethnic Study of Atherosclerosis. <i>Angiology</i> , 2019, 70, 737-746.	0.8	17
71	Risk factors associated with premature myocardial infarction: a systematic review protocol. <i>BMJ Open</i> , 2019, 9, e023647.	0.8	11
72	GlycA, a novel inflammatory marker, is associated with subclinical coronary disease. <i>Aids</i> , 2019, 33, 547-557.	1.0	27

#	ARTICLE	IF	CITATIONS
73	Association of High-Density Lipoprotein Particles and High-Density Lipoprotein Apolipoprotein C-III Content With Cardiovascular Disease Risk According to Kidney Function: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of the American Heart Association</i> , 2019, 8, e013713.	1.6	9
74	Fibroblast growth factor-21 levels in metabolic syndrome: Another instrument in a widening tool belt?. <i>Atherosclerosis</i> , 2019, 281, 143-144.	0.4	2
75	Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2019, 380, 33-44.	13.9	1,141
76	Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 23-32.	13.9	684
77	Directed Non-targeted Mass Spectrometry and Chemical Networking for Discovery of Eicosanoids and Related Oxylipins. <i>Cell Chemical Biology</i> , 2019, 26, 433-442.e4.	2.5	64
78	Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women's Genome Health Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 97-106.	1.1	10
79	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. <i>Current Vascular Pharmacology</i> , 2019, 17, 515-537.	0.8	19
80	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. <i>Current Vascular Pharmacology</i> , 2019, 17, 498-514.	0.8	38
81	Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. <i>Current Atherosclerosis Reports</i> , 2018, 20, 15.	2.0	5
82	The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering. <i>Circulation</i> , 2018, 137, 20-23.	1.6	12
83	Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study. <i>American Journal of Epidemiology</i> , 2018, 187, 705-716.	1.6	40
84	Adiposity and Genetic Factors in Relation to Triglycerides and Triglyceride-Rich Lipoproteins in the Women's Genome Health Study. <i>Clinical Chemistry</i> , 2018, 64, 231-241.	1.5	10
85	Associations of ideal cardiovascular health with GlycA, a novel inflammatory marker: The Multi-Ethnic Study of Atherosclerosis. <i>Clinical Cardiology</i> , 2018, 41, 1439-1445.	0.7	23
86	Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean Diet. <i>JAMA Network Open</i> , 2018, 1, e185708.	2.8	65
87	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet, The</i> , 2018, 392, 1311-1320.	6.3	355
88	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): An Overlooked Form of Hypoglycemia in Clinical Practice. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-6.	0.6	6
89	Altered branched chain amino acid metabolism. <i>Current Opinion in Cardiology</i> , 2018, 33, 558-564.	0.8	34
90	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , 2018, 64, 1006-1033.	1.5	189

#	ARTICLE	IF	CITATIONS
91	Longitudinal Changes in Cholesterol Efflux Capacities in Patients With Coronary Artery Disease Undergoing Lifestyle Modification Therapy. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	3
92	Dietary Intakes and Circulating Concentrations of Branched-Chain Amino Acids in Relation to Incident Type 2 Diabetes Risk Among High-Risk Women with a History of Gestational Diabetes Mellitus. <i>Clinical Chemistry</i> , 2018, 64, 1203-1210.	1.5	64
93	Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. <i>JAMA Internal Medicine</i> , 2018, 178, 1231.	2.6	58
94	Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002157.	1.6	145
95	Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. <i>Journal of the American College of Cardiology</i> , 2018, 72, 287-296.	1.2	73
96	Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence. <i>Circulation</i> , 2018, 138, 2330-2341.	1.6	98
97	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. <i>Clinical Chemistry</i> , 2017, 63, 870-879.	1.5	74
98	Predicting Asthma Exacerbations from a Drop of Blood. <i>Clinical Chemistry</i> , 2017, 63, 799-801.	1.5	1
99	Risk and Benefit Information and Use of Aspirin's Reply. <i>JAMA Internal Medicine</i> , 2017, 177, 291.	2.6	0
100	Effects of statins on the immunoglobulin G glycome. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 1152-1158.	1.1	20
101	Association of Air Pollution Exposures With High-Density Lipoprotein Cholesterol and Particle Number. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 976-982.	1.1	79
102	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. <i>Circulation</i> , 2017, 135, 2494-2504.	1.6	180
103	Impact of Subclinical Hypothyroidism on Cardiometabolic Biomarkers in Women. <i>Journal of the Endocrine Society</i> , 2017, 1, 113-123.	0.1	16
104	Genetic associations with lipoprotein subfraction measures differ by ethnicity in the multi-ethnic study of atherosclerosis (MESA). <i>Human Genetics</i> , 2017, 136, 715-726.	1.8	12
105	Partitioning the Genetic Architecture of Plasma Lipoprotein(a) and Kringle IV Type 2 Repeats: Implications for Therapeutic Lowering. <i>Clinical Chemistry</i> , 2017, 63, 1792-1794.	1.5	0
106	Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	98
107	Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20 years: The Women's Health Study. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1257-1267.e2.	0.6	40
108	Association of High-Density Lipoprotein Cholesterol Versus Apolipoprotein A With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	13

#	ARTICLE	IF	CITATIONS
109	Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	61
110	Is it time to abandon fasting for routine lipid testing?. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 919-922.	0.6	6
111	Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2276.	3.8	0
112	Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	44
113	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints—A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>Clinical Chemistry</i> , 2016, 62, 930-946.	1.5	145
114	Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus. <i>JAMA Cardiology</i> , 2016, 1, 136.	3.0	53
115	Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). <i>American Journal of Cardiology</i> , 2016, 117, 1921-1927.	0.7	43
116	Lipid biomarkers and long-term risk of cancer in the Women's Health Study. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 1397-1407.	2.2	117
117	Nonfasting for Routine Lipid Testing. <i>JAMA Internal Medicine</i> , 2016, 176, 1005.	2.6	38
118	Glycosylation Signatures of Inflammation Identify Cardiovascular Risk. <i>Circulation Research</i> , 2016, 119, 1154-1156.	2.0	17
119	Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 709.	3.8	33
120	Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>JAMA Internal Medicine</i> , 2016, 176, 1195.	2.6	58
121	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>European Heart Journal</i> , 2016, 37, 1944-1958.	1.0	542
122	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. <i>Clinical Chemistry</i> , 2016, 62, 428-435.	1.5	22
123	Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. <i>Circulation Research</i> , 2016, 118, 1106-1115.	2.0	97
124	Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. <i>Science</i> , 2016, 351, 1166-1171.	6.0	438
125	Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. <i>European Heart Journal</i> , 2016, 37, 1373-1379.	1.0	180
126	Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. <i>PLoS ONE</i> , 2016, 11, e0165615.	1.1	31

#	ARTICLE	IF	CITATIONS
127	Re-assessing the role of non-fasting lipids; a change in perspective. <i>Annals of Translational Medicine</i> , 2016, 4, 431-431.	0.7	16
128	Fasting for Laboratory Tests Poses a High Risk of Hypoglycemia in Patients with Diabetes: A Pilot Prevalence Study in Clinical Practice. <i>International Journal of Clinical Medicine</i> , 2016, 07, 653-667.	0.1	5
129	Novel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1544-1550.	1.1	105
130	Lipoprotein Particles and Incident Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis. <i>Diabetes Care</i> , 2015, 38, 628-636.	4.3	120
131	Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. <i>Clinical Chemistry</i> , 2015, 61, 1156-1163.	1.5	53
132	Reply to Letters Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)". <i>Circulation</i> , 2015, 131, e473.	1.6	1
133	Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo. <i>Circulation</i> , 2015, 132, 2220-2229.	1.6	101
134	Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 688-695.	5.1	6
135	A Multivariate Genome-Wide Association Analysis of 10 LDL Subfractions, and Their Response to Statin Treatment, in 1868 Caucasians. <i>PLoS ONE</i> , 2015, 10, e0120758.	1.1	323
136	High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 55-63.	0.9	56
137	Response to Letter Regarding Article, "Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in)". <i>Circulation</i> , 2014, 130, e10.	1.4	10
138	Moving Beyond Mean Glycemia: 1,5-Anhydroglucitol and Microvascular Complications of Diabetes. <i>Clinical Chemistry</i> , 2014, 60, 1359-1361.	1.5	2
139	A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events. <i>Journal of the American Heart Association</i> , 2014, 3, e001221.	1.6	179
140	Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events. <i>Circulation</i> , 2014, 129, 553-561.	1.6	189
141	Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 866-875.	0.8	18
142	Paradoxical Association of Lipoprotein Measures With Incident Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 612-619.	2.1	75
143	The Guidelines Battle on Starting Statins. <i>New England Journal of Medicine</i> , 2014, 370, 1652-1658.	13.9	19
144	Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL). <i>American Journal of Cardiology</i> , 2014, 113, 1378-1382.	0.7	27

#	ARTICLE	IF	CITATIONS
145	Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk. <i>Circulation</i> , 2014, 129, 635-642.	1.6	338
146	Response to Letter Regarding Article, "High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy". <i>Circulation</i> , 2014, 129, e481.	1.6	0
147	Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2014, 64, 485-494.	1.2	512
148	Safety Profile of Subjects Treated to Very Low Low-Density Lipoprotein Cholesterol Levels (30mg/dl) With Rosuvastatin 20mg Daily (from JUPITER). <i>American Journal of Cardiology</i> , 2014, 114, 1682-1689.	0.7	53
149	Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality. <i>Circulation</i> , 2014, 130, 546-553.	1.6	118
150	What's Different about Women's Health?. <i>Clinical Chemistry</i> , 2014, 60, 1-3.	1.5	8
151	Discovery and refinement of loci associated with lipid levels. <i>Nature Genetics</i> , 2013, 45, 1274-1283.	9.4	2,641
152	Common variants associated with plasma triglycerides and risk for coronary artery disease. <i>Nature Genetics</i> , 2013, 45, 1345-1352.	9.4	754
153	Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients. <i>Circulation</i> , 2013, 128, 1504-1512.	1.6	162
154	Value of reserve pulse pressure in improving the risk stratification of patients with normal myocardial perfusion imaging. <i>European Heart Journal</i> , 2013, 34, 2074-2082.	1.0	6
155	Are There Sex Differences in Acute Coronary Syndrome Presentation?. <i>JAMA Internal Medicine</i> , 2013, 173, 1861.	2.6	6
156	High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy. <i>Circulation</i> , 2013, 128, 1189-1197.	1.6	203
157	A Comparison of the Theoretical Relationship between HDL Size and the Ratio of HDL Cholesterol to Apolipoprotein A-I with Experimental Results from the Women's Health Study. <i>Clinical Chemistry</i> , 2013, 59, 949-958.	1.5	48
158	Non-fasting blood testing for lipid screening in children result in statistically significant, but not clinically significant, changes in lipid levels. <i>Evidence-Based Medicine</i> , 2012, 17, 133-134.	0.6	1
159	Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1302.	3.8	650
160	Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy. <i>Circulation</i> , 2012, 125, 1979-1987.	1.6	149
161	Fasting for Lipid Testing: Is It Worth the Trouble?. <i>Archives of Internal Medicine</i> , 2012, 172, 1710.	4.3	22
162	On-Treatment Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1521-1528.	1.2	90

#	ARTICLE	IF	CITATIONS
163	High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events. <i>Journal of the American College of Cardiology</i> , 2012, 60, 508-516.	1.2	325
164	Aspirin Therapy in Primary Prevention. <i>Archives of Internal Medicine</i> , 2012, 172, 217.	4.3	11
165	A National Interactive Web-Based Physical Activity Intervention in Women, Evaluation of the American Heart Association Choose to Move Program 2006-2007. <i>American Journal of Cardiology</i> , 2012, 109, 1754-1760.	0.7	21
166	Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. <i>Journal of Clinical Lipidology</i> , 2011, 5, 105-113.	0.6	311
167	Association of High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein B100 Levels. <i>Annals of Internal Medicine</i> , 2011, 155, 742.	2.0	52
168	Lipoprotein Subclass Abnormalities and Incident Hypertension in Initially Healthy Women. <i>Clinical Chemistry</i> , 2011, 57, 1178-1187.	1.5	42
169	Lifestyle Interaction With Fat Mass and Obesity-Associated (<i>FTO</i>) Genotype and Risk of Obesity in Apparently Healthy U.S. Women. <i>Diabetes Care</i> , 2011, 34, 675-680.	4.3	84
170	Physical Activity Attenuates the Influence of <i>FTO</i> Variants on Obesity Risk: A Meta-Analysis of 218,166 Adults and 19,268 Children. <i>PLoS Medicine</i> , 2011, 8, e1001116.	3.9	446
171	Exercise Treadmill Stress Testing With and Without Imaging. , 2011, , 489-502.		1
172	Providing Patients With Global Cardiovascular Risk Information. <i>Archives of Internal Medicine</i> , 2010, 170, 227.	4.3	9
173	Lipoprotein(a) and Risk of Type 2 Diabetes. <i>Clinical Chemistry</i> , 2010, 56, 1252-1260.	1.5	165
174	Exercise Blood Pressure and Future Cardiovascular Death in Asymptomatic Individuals. <i>Circulation</i> , 2010, 121, 2109-2116.	1.6	130
175	Response to Letters Regarding Article, "Statin for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women from Primary Prevention Trials"; <i>Circulation</i> . 2010. 122, .	1.6	0
176	Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women. <i>Diabetes</i> , 2010, 59, 1153-1160.	0.3	157
177	Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia. <i>Circulation</i> , 2010, 121, 1069-1077.	1.6	287
178	The Fat-Mass and Obesity-Associated (<i>FTO</i>) gene, physical activity, and risk of incident cardiovascular events in white women. <i>American Heart Journal</i> , 2010, 160, 1163-1169.	1.2	51
179	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. <i>Lancet</i> , The, 2010, 376, 333-339.	6.3	221
180	The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines. <i>Clinical Chemistry</i> , 2009, 55, 219-228.	1.5	86

#	ARTICLE	IF	CITATIONS
181	Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use. <i>Circulation</i> , 2009, 119, 2396-2404.	1.6	77
182	Response to Letter Regarding Article, "Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events" <i>Circulation</i> , 2009, 119, .	1.6	4
183	AHA/ACCF 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. <i>Circulation</i> , 2009, 120, 1296-1336.	1.6	117
184	Comparison of LDL Cholesterol Concentrations by Friedewald Calculation and Direct Measurement in Relation to Cardiovascular Events in 27 331 Women. <i>Clinical Chemistry</i> , 2009, 55, 888-894.	1.5	153
185	Aspirin Therapy in Women. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 63-64.	0.9	5
186	Response to Letter Regarding Article, "Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women" <i>Circulation</i> , 2009, 120, .	1.6	1
187	Biphasic Pulmonary Regurgitation. <i>Echocardiography</i> , 2009, 26, 720-723.	0.3	2
188	Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women. <i>Circulation</i> , 2009, 119, 931-939.	1.6	427
189	ACCF/AHA 2009 Performance Measures for Primary Prevention of Cardiovascular Disease in Adults. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1364-1405.	1.2	80
190	Use of High-Sensitivity C-Reactive Protein for Risk Assessment. , 2009, , 158-166.		0
191	Forty-Three Loci Associated with Plasma Lipoprotein Size, Concentration, and Cholesterol Content in Genome-Wide Analysis. <i>PLoS Genetics</i> , 2009, 5, e1000730.	1.5	300
192	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. <i>New England Journal of Medicine</i> , 2008, 359, 2195-2207.	13.9	5,712
193	The use of high-sensitivity assays for C-reactive protein in clinical practice. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 621-635.	3.3	123
194	Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events. <i>Circulation</i> , 2008, 118, 993-1001.	1.6	366
195	Homocysteine, 5,10-Methylenetetrahydrofolate Reductase 677C>T Polymorphism, Nutrient Intake, and Incident Cardiovascular Disease in 24 968 Initially Healthy Women. <i>Clinical Chemistry</i> , 2007, 53, 845-851.	1.5	62
196	Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 309.	3.8	1,326
197	LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). <i>Atherosclerosis</i> , 2007, 192, 211-217.	0.4	322
198	Physical Activity and Reduced Risk of Cardiovascular Events. <i>Circulation</i> , 2007, 116, 2110-2118.	1.6	799

#	ARTICLE	IF	CITATIONS
199	Blood pressure and risk of developing type 2 diabetes mellitus: The Women's Health Study. <i>European Heart Journal</i> , 2007, 28, 2937-2943.	1.0	153
200	Glucose levels in the normal range predict incident diabetes in families with premature coronary heart disease. <i>Diabetes Research and Clinical Practice</i> , 2006, 74, 267-273.	1.1	6
201	The Metabolic Syndrome in Women. <i>Cardiology in Review</i> , 2006, 14, 286-291.	0.6	96
202	Gender-Specific Prediction of Cardiac Disease. <i>Cardiology in Review</i> , 2006, 14, 281-285.	0.6	16
203	Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)â€”Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention?. <i>American Journal of Cardiology</i> , 2006, 97, 33-41.	0.7	182
204	Association of Physical Activity and Body Mass Index With Novel and Traditional Cardiovascular Biomarkers in Women. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1412.	3.8	331
205	Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events. <i>Circulation</i> , 2006, 114, 381-387.	1.6	76
206	Interaction of Body Mass Index and Framingham Risk Score in Predicting Incident Coronary Disease in Families. <i>Circulation</i> , 2005, 111, 1871-1876.	1.6	77
207	Enhanced Risk Assessment in Asymptomatic Individuals With Exercise Testing and Framingham Risk Scores. <i>Circulation</i> , 2005, 112, 1566-1572.	1.6	90
208	Ability of Exercise Testing to Predict Cardiovascular and All-Cause Death in Asymptomatic Women. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 1600-7.	3.8	472
209	Coronary artery disease in postmenopausal women. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2001, 3, 67-79.	0.4	6
210	Certain cardiac risk factors predict risk factor interventions and influence communication between physicians and patients. <i>American Journal of Cardiology</i> , 2000, 86, 783-785.	0.7	1
211	Mediterranean diet social network impact along 11 years in the major US media outlets: Thematic and Quantitative Analysis using Twitter. (Preprint). <i>JMIR Public Health and Surveillance</i> , 0, , .	1.2	0